Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib plus cisplatin/vinorelbine versus cisplatin/vinorelbine for advanced non-small cell lung cancer
ChiCTR-TNRC-11001601Phase 2Completed
- Sponsor
- Shanghai Chest Hospital
- Start
- Apr 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of celecoxib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: Overall survival. Started Apr 2010; status: completed.
02
Drugs
celecoxib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-TNRC-11001601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNRC-11001601.